Diabetes mellitus, a chronic metabolic disorder, imposes a significant global health burden, with type 2 diabetes (T2D) accounting for the majority of cases. Over the past decade, sodium-glucose cotransporter-2 (SGLT2) inhibitors have transformed the therapeutic landscape for T2D management. These agents operate by selectively blocking glucose reabsorption in the proximal renal tubule, thereby promoting glucosuria and lowering plasma glucose through an insulin-independent mechanism. While the glycemic efficacy and short-term tolerability of SGLT2 inhibitors are well established, the long-term outcomes—spanning cardiovascular, renal, and metabolic endpoints—are critical for clinicians making treatment decisions that span years to decades. This article provides an authoritative assessment of long-term clinical data for SGLT2 inhibitors in diabetes research, emphasizing safety, efficacy, and future directions.

Introduction to SGLT2 Inhibitors

The development of SGLT2 inhibitors emerged from the recognition that the kidney plays a central role in glucose homeostasis. Under normal circumstances, the kidney filters approximately 180 grams of glucose daily, with SGLT2 receptors in the proximal convoluted tubule responsible for reabsorbing 90% of that glucose. By inhibiting these transporters, SGLT2 agents lower the renal threshold for glucose, producing sustained urinary glucose excretion of 60–100 grams per day. Approved members of this class include canagliflozin, dapagliflozin, empagliflozin, ertugliflozin, and others, each with slight pharmacokinetic differences but similar core mechanisms.

Mechanism of Action and Pleiotropic Effects

Beyond glycemic control, SGLT2 inhibitors exert a range of pleiotropic effects that contribute to their long-term benefits. These include osmotic diuresis and natriuresis leading to reduced plasma volume, improved arterial stiffness through reduced oxidative stress, and metabolic shifts toward fat utilization through increased ketone body production. These mechanisms underpin the cardiovascular and renal protection observed in large-scale outcome trials.

Historical Context and Trial Milestones

The era of SGLT2 inhibitor outcome trials began with the EMPA-REG OUTCOME study (2015), which demonstrated a 38% relative risk reduction in cardiovascular death with empagliflozin in patients with T2D and established cardiovascular disease. This was followed by the CANVAS Program (2017) for canagliflozin, the DECLARE-TIMI 58 trial (2018) for dapagliflozin, and the VERTIS CV trial (2020) for ertugliflozin. Each trial contributed unique insights into long-term efficacy and safety across diverse patient populations.

Long-term Clinical Outcomes

Long-term assessments from these trials, extending up to 5–6 years of follow-up, have yielded consistent findings across multiple endpoints. The primary outcomes of interest include major adverse cardiovascular events (MACE), hospitalization for heart failure (HHF), renal composite outcomes, and all-cause mortality.

Cardiovascular Benefits

The cardiovascular benefits of SGLT2 inhibitors have been a paradigm shift in diabetes management. In the EMPA-REG OUTCOME trial, empagliflozin reduced the risk of 3-point MACE by 14% (HR 0.86; 95% CI 0.74–0.99), driven largely by a 38% reduction in cardiovascular death. These benefits emerged early and were sustained over the median 3.1-year follow-up. Importantly, the reduction in HHF was robust, with risk reductions of approximately 35% across trials. The DECLARE-TIMI 58 trial, which included a broader primary prevention cohort, showed that dapagliflozin reduced the composite of HHF or cardiovascular death by 17% (HR 0.83; 95% CI 0.73–0.95), although MACE reduction did not reach statistical significance in the overall population because the benefit was concentrated in those with prior myocardial infarction.

Long-term persistence of cardiovascular benefit has been supported by extended follow-up analyses. For example, the EMPA-REG OUTCOME investigators published 6-year follow-up data showing that the reduction in cardiovascular death persisted with extended observation. Similarly, the CREDENCE trial evaluated canagliflozin in T2D patients with chronic kidney disease (CKD) and demonstrated a 20% reduction in the composite of cardiovascular death, myocardial infarction, or stroke (HR 0.80; 95% CI 0.67–0.95) over a median 2.62 years. These results have been corroborated by real-world evidence from large databases, including the CVD-REAL study, which showed consistent reductions in HHF and all-cause mortality across clinical practice settings.

The mechanism of cardiovascular protection appears to involve hemodynamic and metabolic effects independent of glycemic improvement. The SGLT2 inhibitor-induced osmotic diuresis reduces preload and afterload, while the shift to ketone metabolism enhances myocardial efficiency in failing hearts—an effect observed in both diabetic and nondiabetic heart failure populations. The DAPA-HF trial (2019) extended these benefits to patients with heart failure with reduced ejection fraction (HFrEF) regardless of diabetes status, solidifying the role of SGLT2 inhibitors as foundational therapy for heart failure.

Renal Protection

Renal protection is arguably one of the most consequential long-term outcomes associated with SGLT2 inhibitors. Diabetic kidney disease (DKD) remains the leading cause of end-stage renal disease (ESRD) worldwide, and effective interventions have been limited. The CREDENCE trial, specifically designed to evaluate renal outcomes, demonstrated that canagliflozin reduced the composite of ESRD, doubling of serum creatinine, or renal/cardiovascular death by 30% (HR 0.70; 95% CI 0.59–0.82) in patients with T2D and albuminuric CKD (eGFR 30–<90 mL/min/1.73 m², UACR >300 mg/g). This benefit was additive to maximal renin-angiotensin-aldosterone system blockade.

Subsequent trials, including DAPA-CKD (dapagliflozin in CKD with or without T2D) and EMPA-KIDNEY (empagliflozin in CKD with or without T2D), have confirmed robust renoprotective effects across a broader spectrum of kidney disease. DAPA-CKD showed a 39% reduction in the composite of sustained eGFR decline ≥50%, ESRD, or renal/cardiovascular death (HR 0.61; 95% CI 0.51–0.72) in patients with eGFR 25–75 mL/min/1.73 m² and UACR 200–5000 mg/g. EMPA-KIDNEY, which included patients with eGFR as low as 20 mL/min/1.73 m², demonstrated a 28% reduction in progression of kidney disease or cardiovascular death (HR 0.72; 95% CI 0.64–0.82).

The long-term renal benefits are attributed to several mechanisms: reduction of intraglomerular pressure via tubuloglomerular feedback, attenuation of renal hypoxia through improved oxygen delivery/demand balance, and suppression of profibrotic pathways such as TGF-β1 and inflammatory cytokines. Importantly, the initial dip in eGFR (a "hemodynamic" effect) observed in the first weeks of therapy is not indicative of true nephrotoxicity; rather, it reflects a reversible decrease in hyperfiltration, which translates into durable nephroprotection over years. A meta-analysis of large outcome trials published in The Lancet (2023) confirmed that SGLT2 inhibitors reduce the risk of kidney failure by 33% in the DKD population.

Mortality and Risk of Death

All-cause mortality reduction remains a critical measure of long-term outcome. In EMPA-REG OUTCOME, empagliflozin reduced all-cause mortality by 32% (HR 0.68; 95% CI 0.57–0.82). DECLARE-TIMI 58 and CANVAS showed numerically lower all-cause mortality but did not reach statistical significance in the overall population; however, meta-analyses including all class members demonstrate a consistent reduction in all-cause mortality of approximately 15–20%. The CREDENCE trial reported a 17% reduction in all-cause death (HR 0.83; 95% CI 0.68–1.02), which fell just short of significance but trended favorably. In DAPA-HF, all-cause mortality was reduced by 17% (HR 0.83; 95% CI 0.71–0.97), providing evidence that mortality benefit extends to nondiabetic heart failure populations.

Metabolic and Weight Effects

Long-term weight loss is consistently observed with SGLT2 inhibitors. The mean weight reduction ranges from 2 to 4 kg and appears to be sustained for the duration of therapy, though a plateau often occurs after 6–12 months. This effect is primarily due to caloric loss through glucosuria (approximately 200–300 kcal/day) but also involves changes in energy expenditure and possibly reduced appetite. Importantly, weight loss with SGLT2 inhibitors is predominantly fat mass reduction, with preservation of lean muscle mass. Additionally, SGLT2 inhibitors produce modest reductions in systolic blood pressure (3–5 mmHg) and serum uric acid levels, further supporting long-term cardiovascular risk reduction.

Safety Profile and Adverse Effects in Long-term Use

Long-term safety data from trials with up to 6 years of follow-up—and real-world studies with even longer exposure—have identified a well-characterized safety profile. The most common adverse effects are related to the mechanism of action and include increased risk of genital mycotic infections (e.g., vulvovaginal candidiasis, balanitis), with incidence rates of 5–10% and higher in women and uncircumcised men. Urinary tract infections (UTIs) are mildly increased, especially in the first few months, though the absolute risk is modest. Volume depletion events (hypotension, dehydration) are dose-dependent and more common in patients using loop diuretics, elderly patients, or those with compromised renal function at baseline.

Diabetic Ketoacidosis (DKA) in T2D

A rare but serious long-term safety concern is euglycemic or normoglycemic DKA (euDKA). Unlike classic DKA, blood glucose levels may be <200 mg/dL, delaying diagnosis. The incidence rate is approximately 0.1–0.4 events per 100 patient-years in T2D, but risk factors include insulinopenia, acute illness, surgery, caloric restriction, and excessive alcohol consumption. The mechanism involves increased ketogenesis due to reduced glucose uptake by hepatocytes and increased glucagon-to-insulin ratio. Management requires immediate discontinuation of the SGLT2 inhibitor, aggressive intravenous fluids and dextrose, and insulin therapy. The FDA issued a safety alert in 2020 emphasizing heightened awareness.

Amputation Risk and Fractures

The CANVAS Program reported an increased risk of lower limb amputations (mostly toe or metatarsal) with canagliflozin (6.3 vs 3.4 per 1000 patient-years), leading to a boxed warning in the United States for canagliflozin. However, subsequent trials with canagliflozin (CREDENCE) and other SGLT2 inhibitors did not show a statistically significant increase, suggesting this may be a dose- or population-specific effect. Similarly, an initial signal for increased bone fracture (especially of the upper extremity) with canagliflozin in CANVAS prompted investigation. Long-term data from DAPA-CKD and EMPA-KIDNEY have not confirmed a fracture risk, though careful monitoring in high-risk patients (osteoporosis, falls risk) is prudent.

Renal Function Considerations

As noted, an acute reversible decline in eGFR (often 3–5 mL/min/1.73 m²) is a class effect during the first 2–4 weeks. This should not prompt drug discontinuation unless accompanied by other signs of injury. Long-term trials have demonstrated sustained eGFR slope preservation, with a difference in annual eGFR decline of 0.5–1.5 mL/min/1.73 m² per year favoring SGLT2 inhibitors versus placebo. However, patients with a baseline eGFR below 20–25 mL/min/1.73 m² were excluded from most trials, and the use of SGLT2 inhibitors at very low eGFR (e.g., <20 mL/min/1.73 m²) is not approved for glycemic efficacy, though renal protective benefits may still be present as suggested by EMPA-KIDNEY.

Other Long-term Safety Concerns

Rare adverse events include Fournier gangrene (necrotizing fasciitis of the perineum), which has been reported at a very low incidence (0.08% in clinical trials) and requires urgent surgical intervention. Acute pancreatitis, hypersensitivity reactions, and hepatotoxicity have not been significantly elevated in long-term data. Overall, the benefit-risk balance strongly favors the use of SGLT2 inhibitors in patients with T2D who have or are at high risk for cardiovascular and renal disease, provided appropriate counseling and monitoring are implemented.

Comparative Efficacy with Other Glucose-lowering Agents

When considering long-term outcomes, SGLT2 inhibitors have been compared head-to-head with other classes, particularly glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and DPP-4 inhibitors. In network meta-analyses, SGLT2 inhibitors are generally superior to DPP-4 inhibitors for cardiovascular and renal outcomes, and their effectiveness may be complementary to GLP-1 RAs. The combination of an SGLT2 inhibitor and a GLP-1 RA offers additive benefits for MACE and HHF reduction, as well as weight loss, and is increasingly recommended by major guidelines (ADA, ESC, KDIGO). Importantly, SGLT2 inhibitors have a unique advantage in reducing HHF compared with GLP-1 RAs, which show more pronounced MACE reduction but less robust effects on heart failure. Long-term adherence to SGLT2 inhibitors is generally good, with persistence rates at 2–3 years of 60–80% in real-world analyses, comparable to or better than other oral agents.

Future Directions in Research

Ongoing research is poised to refine our understanding of the long-term implications of SGLT2 inhibitor therapy. Several key areas are under active investigation: the role of SGLT2 inhibitors in early-stage kidney disease (prevention of incident albuminuria), combination therapy with mineralocorticoid receptor antagonists (MRAs) such as finerenone, and the clinical utility of these agents in nondiabetic chronic kidney disease (already demonstrated in DAPA-CKD and EMPA-KIDNEY, but long-term renal survival data are awaited).

Another frontier is the application of SGLT2 inhibitors in type 1 diabetes, where the risk of DKA is higher. Trials such as DEPICT (dapagliflozin) and inTandem (sotagliflozin) have shown improved glycemic control and reduced insulin requirements but with increased DKA risk. Long-term safety in type 1 diabetes remains unresolved, and regulatory approval has been limited. Additionally, the potential for SGLT2 inhibitors in treating nonalcoholic fatty liver disease (NAFLD) is being explored based on metabolic benefits, with early trials showing reductions in liver fat content.

Precision medicine approaches—such as identifying biomarkers predicting optimal response or susceptibility to adverse effects—will be critical. Pharmacogenomic studies may identify genetic variants affecting SGLT2 expression or renal handling that modulate outcomes. Furthermore, the long-term economic impact and quality-of-life assessments are essential for health policy decisions. As generic versions of SGLT2 inhibitors become available, access and cost-effectiveness will be major considerations, particularly in low-income settings where diabetic complications are most prevalent.

Summary of Long-term Recommendations

Based on the totality of evidence from randomized controlled trials, meta-analyses, and real-world studies spanning up to 6 years of follow-up, SGLT2 inhibitors are a cornerstone of long-term therapy in patients with type 2 diabetes who have established cardiovascular disease, multiple risk factors, heart failure, or chronic kidney disease. Their long-term benefits on cardiovascular death, HHF, renal progression, and all-cause mortality are robust and class-wide, though canagliflozin carries a specific amputation warning that warrants careful shared decision-making. Initiation should consider baseline renal function (eGFR ≥20–25 mL/min/1.73 m² for most agents), volume status, and patient preferences. Ongoing surveillance for adverse events—especially DKA, genital infections, and volume depletion—is necessary throughout treatment. With appropriate monitoring, SGLT2 inhibitors provide sustained organ protection that dramatically changes the natural history of diabetes-associated cardiovascular-kidney disease.